• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's Intraday Session

    6/21/23 1:37:39 PM ET
    $AHI
    $ALDX
    $CMRA
    $EVLO
    Package Goods/Cosmetics
    Consumer Discretionary
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AHI alert in real time by email

    Gainers

    • Advanced Health (NASDAQ:AHI) stock increased by 127.0% to $1.68 during Wednesday's regular session. Trading volume for this security as of 13:37 EST is 84.4 million, which is 2216.8% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $47.0 million.
    • LumiraDx (NASDAQ:LMDX) stock rose 25.0% to $0.44. Trading volume for this security as of 13:37 EST is 19.6 million, which is 8161.9% of its average full-day volume over the last 100 days. The company's market cap stands at $139.3 million.
    • Ocean Biomedical (NASDAQ:OCEA) stock moved upwards by 22.74% to $6.53. Ocean Biomedical's stock is trading at a volume of 35.9 million shares as of 13:37 EST. This is 2593.3% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $222.1 million.
    • Mallinckrodt (AMEX:MNK) shares moved upwards by 16.92% to $1.52. Mallinckrodt's stock is trading at a volume of 521.8K shares as of 13:37 EST. This is 33.4% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $20.0 million.
    • Comera Life Sciences (NASDAQ:CMRA) stock increased by 16.48% to $0.54. The company's market cap stands at $11.9 million.
    • Nutex Health (NASDAQ:NUTX) shares increased by 15.9% to $0.49. Trading volume for this security as of 13:37 EST is 7.1 million, which is 337.6% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $321.5 million.

    Losers

    • Oncorus (NASDAQ:ONCR) stock decreased by 57.4% to $0.06 during Wednesday's regular session. The current volume of 4.5 million shares is 103.8% of Oncorus's average full-day volume over the last 100 days (last updated at 13:37 EST). The market value of their outstanding shares is at $1.4 million.
    • SCWorx (NASDAQ:WORX) stock fell 24.86% to $0.41. The current volume of 1.7 million shares is 54.2% of SCWorx's average full-day volume over the last 100 days (last updated at 13:37 EST). The market value of their outstanding shares is at $5.3 million.
    • Aldeyra Therapeutics (NASDAQ:ALDX) shares declined by 24.73% to $8.01. Trading volume for this security as of 13:37 EST is 4.8 million, which is 433.9% of its average full-day volume over the last 100 days. The company's market cap stands at $469.1 million.
    • Innovative Eyewear (NASDAQ:LUCY) stock decreased by 19.47% to $1.57. Trading volume for Innovative Eyewear's stock is 1.0 million as of 13:37 EST. This is 50.7% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $13.2 million.
    • Navidea Biopharmaceutical (AMEX:NAVB) stock fell 17.24% to $0.09. As of 13:37 EST, Navidea Biopharmaceutical's stock is trading at a volume of 6.4 million, which is 138.9% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $3.1 million.
    • Evelo Biosciences (NASDAQ:EVLO) stock decreased by 17.14% to $0.15. Evelo Biosciences's stock is trading at a volume of 20.4 million shares as of 13:37 EST. This is 228.0% of its average full-day volume over the last 100 days. The company's market cap stands at $16.3 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AHI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AHI
    $ALDX
    $CMRA
    $EVLO

    CompanyDatePrice TargetRatingAnalyst
    Aldeyra Therapeutics Inc.
    $ALDX
    3/18/2026$2.00Buy → Neutral
    H.C. Wainwright
    Nutex Health Inc.
    $NUTX
    11/12/2024$45.00 → $50.00Buy
    Maxim Group
    Nutex Health Inc.
    $NUTX
    9/18/2024$45.00Buy
    Maxim Group
    Advanced Health Intelligence Ltd.
    $AHI
    5/30/2024Buy → Hold
    Maxim Group
    Aldeyra Therapeutics Inc.
    $ALDX
    4/3/2024$10.00Perform → Outperform
    Oppenheimer
    Aldeyra Therapeutics Inc.
    $ALDX
    4/2/2024$10.00Buy
    H.C. Wainwright
    Nutex Health Inc.
    $NUTX
    2/22/2023$3.00Outperform
    Northland Capital
    Aldeyra Therapeutics Inc.
    $ALDX
    4/27/2022$15.00Buy
    H.C. Wainwright
    More analyst ratings

    $AHI
    $ALDX
    $CMRA
    $EVLO
    SEC Filings

    View All

    SEC Form 8-K filed by Aldeyra Therapeutics Inc.

    8-K - Aldeyra Therapeutics, Inc. (0001341235) (Filer)

    4/1/26 4:25:05 PM ET
    $ALDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by SCWorx Corp.

    10-K - SCWorx Corp. (0001674227) (Filer)

    3/31/26 3:07:12 PM ET
    $WORX
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    Amendment: SEC Form SCHEDULE 13G/A filed by Aldeyra Therapeutics Inc.

    SCHEDULE 13G/A - Aldeyra Therapeutics, Inc. (0001341235) (Subject)

    3/26/26 3:26:11 PM ET
    $ALDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AHI
    $ALDX
    $CMRA
    $EVLO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Aldeyra Therapeutics downgraded by H.C. Wainwright with a new price target

    H.C. Wainwright downgraded Aldeyra Therapeutics from Buy to Neutral and set a new price target of $2.00

    3/18/26 8:20:05 AM ET
    $ALDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Maxim Group reiterated coverage on Nutex Health with a new price target

    Maxim Group reiterated coverage of Nutex Health with a rating of Buy and set a new price target of $50.00 from $45.00 previously

    11/12/24 8:15:57 AM ET
    $NUTX
    Real Estate

    Maxim Group initiated coverage on Nutex Health with a new price target

    Maxim Group initiated coverage of Nutex Health with a rating of Buy and set a new price target of $45.00

    9/18/24 8:12:45 AM ET
    $NUTX
    Real Estate

    $AHI
    $ALDX
    $CMRA
    $EVLO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Innovative Eyewear, Inc. Announces New Smart Safety Glasses and Rx Safety Partner

    MIAMI, March 31, 2026 /PRNewswire/ -- Innovative Eyewear, Inc. ("Innovative Eyewear" or the "Company") (NASDAQ: LUCY; LUCYW), the developer & manufacturer of smart eyewear under the Lucyd®, Lucyd Armor®, Reebok®, Nautica®, and Eddie Bauer® brands, is pleased to announce the launch of the new Lucyd Armor® Vantage style. The new smart safety frame is fully certified for workplace use under US, Canadian and European standards. The frame will debut on March 31, 2026 at the National Hardware Show: Concept to Commerce event in Las Vegas. The frame will launch on the Company's website as well as with its new premier reseller for the safety channel, Ocusafe.com.

    3/31/26 8:00:00 AM ET
    $LUCY
    Ophthalmic Goods
    Health Care

    Innovative Eyewear Inc. Reports Full Year 2025 Financial Results

    Revenue increased 63% over prior year Gross Profit Margins increased by 8 percentage points despite tariff headwindsMIAMI, March 25, 2026 /PRNewswire/ -- Innovative Eyewear Inc., (NASDAQ:LUCY, LUCYW)), the developer of smart eyewear under the Lucyd®, Lucyd Armor®, Reebok®, Nautica®, and Eddie Bauer® brands, today announced its full year 2025 financial results. Net revenue for the year ended December 31, 2025 was approximately $2.67 million, an increase of $1.03 million or 63% from the year ended December 31, 2024. This strong year-over-year revenue growth was primarily driven by

    3/25/26 4:30:00 PM ET
    $LUCY
    Ophthalmic Goods
    Health Care

    Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Signs and Symptoms of Dry Eye Disease

    Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced receipt of a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for the New Drug Application (NDA) of reproxalap, an investigational drug candidate, for the treatment of dry eye disease. The CRL stated that there is "a lack of substantial evidence consisting of adequate and well-controlled investigations … that the drug product will have the effect it purports or is represented to have under the conditions of use prescribed, recommended, or suggested in its proposed labe

    3/17/26 8:30:00 AM ET
    $ALDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AHI
    $ALDX
    $CMRA
    $EVLO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Legal Officer-Healthcare Montgomery Pamela W. bought $7,021 worth of shares (79 units at $88.87), increasing direct ownership by 3% to 2,758 units (SEC Form 4)

    4 - Nutex Health Inc. (0001479681) (Issuer)

    3/16/26 3:02:43 PM ET
    $NUTX
    Real Estate

    Chief Executive Officer Gross Harrison R. bought $1,980 worth of shares (1,500 units at $1.32), increasing direct ownership by 12% to 13,733 units (SEC Form 4)

    4 - Innovative Eyewear Inc (0001808377) (Issuer)

    1/22/26 11:29:05 AM ET
    $LUCY
    Ophthalmic Goods
    Health Care

    Chief Financial Officer Gayle Oswald bought $1,669 worth of shares (1,000 units at $1.67), increasing direct ownership by 54% to 2,865 units (SEC Form 4)

    4 - Innovative Eyewear Inc (0001808377) (Issuer)

    1/15/26 5:00:07 PM ET
    $LUCY
    Ophthalmic Goods
    Health Care

    $AHI
    $ALDX
    $CMRA
    $EVLO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Brady Todd C

    4 - Aldeyra Therapeutics, Inc. (0001341235) (Issuer)

    3/31/26 4:17:57 PM ET
    $ALDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Bamburg Wesley Shane

    4 - Nutex Health Inc. (0001479681) (Issuer)

    3/24/26 3:41:46 PM ET
    $NUTX
    Real Estate

    SEC Form 4 filed by Hosseinion Warren

    4 - Nutex Health Inc. (0001479681) (Issuer)

    3/23/26 1:21:13 PM ET
    $NUTX
    Real Estate

    $AHI
    $ALDX
    $CMRA
    $EVLO
    Leadership Updates

    Live Leadership Updates

    View All

    Innovative Eyewear, Inc. Announces New Smart Safety Glasses and Rx Safety Partner

    MIAMI, March 31, 2026 /PRNewswire/ -- Innovative Eyewear, Inc. ("Innovative Eyewear" or the "Company") (NASDAQ: LUCY; LUCYW), the developer & manufacturer of smart eyewear under the Lucyd®, Lucyd Armor®, Reebok®, Nautica®, and Eddie Bauer® brands, is pleased to announce the launch of the new Lucyd Armor® Vantage style. The new smart safety frame is fully certified for workplace use under US, Canadian and European standards. The frame will debut on March 31, 2026 at the National Hardware Show: Concept to Commerce event in Las Vegas. The frame will launch on the Company's website as well as with its new premier reseller for the safety channel, Ocusafe.com.

    3/31/26 8:00:00 AM ET
    $LUCY
    Ophthalmic Goods
    Health Care

    NUTEX HEALTH ANNOUNCES THE APPOINTMENT OF WESLEY BAMBURG AS ITS NEW CHIEF OPERATING OFFICER

    HOUSTON, Sept. 22, 2025 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ:NUTX), a physician-led, integrated healthcare delivery system comprised of 24 state-of-the-art micro hospitals and hospital outpatient departments  in 11 states and primary care-centric, risk-bearing physician networks, today announced the appointment of Wesley Bamburg as the Company's Chief Operating Officer, effective October 13, 2025. Mr. Bamburg is an accomplished healthcare executive with 20 years of Fortune 500 experience in healthcare operations, business development, integrated network management, and physician relations. Mr. Bamburg has served as Chief Operating Officer for HCA Houst

    9/22/25 6:30:00 AM ET
    $NUTX
    Real Estate

    SCWorx Corp. Appoints New Chief Technology Officer to Accelerate Innovation in Healthcare Data Solutions

    Tampa, FL, Sept. 03, 2025 (GLOBE NEWSWIRE) -- SCWorx Corp. (NASDAQ:WORX), a leading provider of data management and software solutions for the healthcare industry, today announced the appointment of Anders Ohlsson, a seasoned technology executive, as its new Chief Technology Officer (CTO). This strategic hire underscores SCWorx's commitment to advancing its data platform and expanding its suite of data management and software solutions for healthcare providers. Mr. Ohlsson has over 25 years of experience in software engineering, cloud infrastructure, and machine learning applications. Prior to joining SCWorx, he held senior leadership roles at WideOrbit, where he spearheaded the developm

    9/3/25 11:44:49 AM ET
    $WORX
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    $AHI
    $ALDX
    $CMRA
    $EVLO
    Financials

    Live finance-specific insights

    View All

    Innovative Eyewear Inc. Reports Full Year 2025 Financial Results

    Revenue increased 63% over prior year Gross Profit Margins increased by 8 percentage points despite tariff headwindsMIAMI, March 25, 2026 /PRNewswire/ -- Innovative Eyewear Inc., (NASDAQ:LUCY, LUCYW)), the developer of smart eyewear under the Lucyd®, Lucyd Armor®, Reebok®, Nautica®, and Eddie Bauer® brands, today announced its full year 2025 financial results. Net revenue for the year ended December 31, 2025 was approximately $2.67 million, an increase of $1.03 million or 63% from the year ended December 31, 2024. This strong year-over-year revenue growth was primarily driven by

    3/25/26 4:30:00 PM ET
    $LUCY
    Ophthalmic Goods
    Health Care

    Innovative Eyewear, Inc. Announces Q4 and Full Year 2025 Earnings Conference Call

    MIAMI, March 10, 2026 /PRNewswire/ -- Innovative Eyewear, Inc. ("Innovative Eyewear" or the "Company") (NASDAQ: LUCY; LUCYW), the developer & manufacturer of smart eyewear under the Lucyd®, Lucyd Armor®, Reebok®, Nautica®, and Eddie Bauer® brands, today announced its upcoming earnings conference call to share the Company's key operational and financial results for the fiscal year ended December 31, 2025. Earnings Call DetailsDate: Tuesday, March 31, 2026Time: 12:00 PM ETParticipant Listening OptionsInterested participants can join the event by using the dial-in numbers, or by cl

    3/10/26 4:30:00 PM ET
    $LUCY
    Ophthalmic Goods
    Health Care

    NUTEX HEALTH REPORTS 2025 FINANCIAL RESULTS AND ANNOUNCES SECOND STOCK REPURCHASE PROGRAM

    FULL YEAR 2025 HIGHLIGHTS:Total revenue of $875.3 million for the year 2025 versus $479.9 million for the year 2024, an increase of 82.4%Net income attributable to Nutex Health of $70.8 million for 2025 versus net income of $52.1 million for 2024, an increase of $18.7 millionDiluted EPS of $10.48 for 2025 versus diluted EPS of $9.69 for 2024EBITDA of $168.6 million for 2025 versus $98.8 million for 2024, an increase of 70.6%Adjusted EBITDA of $259.6 million for 2025 versus $102.8 million for 2024, an increase of 152.6%Net cash from operating activities of $248.1 million for 2025HOUSTON, March 5, 2026 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ:NUTX), today ann

    3/5/26 6:33:00 PM ET
    $NUTX
    Real Estate

    $AHI
    $ALDX
    $CMRA
    $EVLO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by SCWorx Corp.

    SC 13G - SCWorx Corp. (0001674227) (Subject)

    12/5/24 7:17:43 AM ET
    $WORX
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    SEC Form SC 13G filed by SCWorx Corp.

    SC 13G - SCWorx Corp. (0001674227) (Subject)

    11/26/24 5:02:01 PM ET
    $WORX
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Aldeyra Therapeutics Inc.

    SC 13G/A - Aldeyra Therapeutics, Inc. (0001341235) (Subject)

    11/14/24 4:50:29 PM ET
    $ALDX
    Biotechnology: Pharmaceutical Preparations
    Health Care